scholarly journals Promising Roles of Exosomal microRNAs in Systemic Lupus Erythematosus

2021 ◽  
Vol 12 ◽  
Author(s):  
Wenqian Wang ◽  
Chenran Yue ◽  
Sheng Gao ◽  
Shuting Li ◽  
Jianan Zhou ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Signaling Pathways ◽  
Lupus Erythematosus ◽  
Biological Fluids ◽  
Immunomodulatory Effects ◽  
Systemic Lupus ◽  
Non Invasive ◽  
Donor Cells ◽  
Exosomal Mirnas ◽  
Exosomal Mirna

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by the loss of immune tolerance. Lupus nephritis (LN) is still a major cause of the morbidity and mortality of SLE. In clinical practice, diagnosis, and therapy of SLE is complicated and challenging due to lack of ideal biomarkers. Exosomes could be detected from numerous kinds of biological fluids and their specific contents are considered as hallmarks of autoimmune diseases. The exosomal miRNA profiles of SLE/LN patients significantly differ from those of the healthy controls making them as attractive biomarkers for renal injury. Exosomes are considered as optimal delivery vehicles owing to their higher stable, minimal toxicity, lower immunogenicity features and specific target effects. Endogenous miRNAs can be functionally transferred by exosomes from donor cells to recipient cells, displaying their immunomodulatory effects. In addition, it has been confirmed that exosomal miRNAs could directly interact with Toll-like receptors (TLRs) signaling pathways to regulate NF-κB activation and the secretion of inflammatory cytokines. The present Review mainly focuses on the immunomodulatory effects of exosomal-miRNAs, the complex interplay between exosomes, miRNAs and TLR signaling pathways, and how the exosomal-miRNAs can become non-invasive diagnostic molecules and potential therapeutic strategies for the management of SLE.

The Different Immunomodulation of Indirect Moxibustion on Normal Subjects and Patients with Systemic Lupus Erythematosus

2006 ◽  
Vol 34 (01) ◽  
pp. 47-56 ◽  
Author(s):  
Yen-Ying Kung ◽  
Fang-Pey Chen ◽  
Shinn-Jang Hwang
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Lymphocytes ◽  
Lupus Erythematosus ◽  
Disease Status ◽  
Normal Subjects ◽  
Indirect Moxibustion ◽  
Acupuncture Points ◽  
Immunomodulatory Effects ◽  
Systemic Lupus ◽  
Abnormal Immune Response

Moxibustion has been thought to enhance immunity in healthy condition, but suppress abnormal immune response in disease status. We collected 12 patients with systemic lupus erythematosus (SLE) and 12 healthy women who received indirect moxibustion on acupuncture points ST-36 (Zusanli) and SP-6 (Sanyinjiao) 20 minutes per day for 1 week. During the course, there were no changes of their regular medications or intercurrent infections in normal subjects and SLE patients. We found that indirect moxibustion for 1 week could elevate CD3+ and CD4+ T-lymphocytes in normal subjects, whereas decrease relative proportions of CD8+ T-lymphocytes in patients with SLE. This result confirms that indirect moxibustion has different immunomodulation in normal condition and autoimmune status. However, whether immunomodulatory effects of indirect moxibustion are beneficial for normal subjects and patients with SLE require further confirmation.

Risonanza magnetica e H-MRS dell'encefalo in soggetti con LES ad esordio pediatrico

1997 ◽  
Vol 10 (2_suppl) ◽  
pp. 28-30 ◽  
Author(s):  
M. Mortilla ◽  
M. Ermini ◽  
M. Nistri ◽  
G. Dal Pozzo ◽  
F. Falcini
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Magnetic Resonance ◽  
Lupus Erythematosus ◽  
Risonanza Magnetica ◽  
Systemic Lupus ◽  
Non Invasive ◽  
Children And Young Adults ◽  
Severity Of The Disease ◽  
Invasive Techniques ◽  
Metabolic Information

Systemic lupus erythematosus can produce disturbances in the CNS, characterized by seizures, headache, encephalopathy, chorea, cerebral infarction and psychosis. We used magnetic resonance and spectroscopy, in order to provide anatomical and metabolic information on the direct involvement of the CNS in LES. This study shows how these non-invasive techniques are well tolerated by children and young adults and how the levels of N-acetylaspartate correlate with the severity of the disease.

scholarly journals Screening for hub genes and signaling pathways of CD8+ T cells in systemic lupus erythematosus using bioinformatics

2021 ◽  
Vol 271 ◽  
pp. 03034
Author(s):  
Yuefeng Wu
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Cells ◽  
Signaling Pathways ◽  
Cd8 T Cells ◽  
Lupus Erythematosus ◽  
Diagnosis And Treatment ◽  
Pathway Enrichment Analysis ◽  
Systemic Lupus ◽  
Hub Genes ◽  
Potential Biomarker

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, which can damage multiple organs. The adaptive immune system, including CD8+ T cells, plays an essential role in this disease. However, the pathogenesis of SLE remains unclear, and there is a lack of effective diagnosis and treatment methods for SLE. In particular, there has been little research on SLE biomarkers, which have been widely studied and used in cancer diagnosis and treatment. In this study, bioinformatics tools were used to screen for hub genes and signaling pathways involving CD8+ T cells in patients with SLE. This is the first determination of metabolic abnormalities in SLE CD8+ T cells using bioinformatics pathway enrichment analysis. The PPI network and MCC algorithm identified SKP2 as a potential biomarker for SLE.

scholarly journals An Overview of the Safety, Efficiency, and Signal Pathways of Stem Cell Therapy for Systemic Lupus Erythematosus

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Qian Yang ◽  
Yiping Liu ◽  
Guangyong Chen ◽  
Wancong Zhang ◽  
Shijie Tang ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Stem Cell ◽  
Autoimmune Disease ◽  
Serum Creatinine ◽  
Signaling Pathways ◽  
Lupus Erythematosus ◽  
Inflammatory Factors ◽  
Signal Pathways ◽  
Systemic Lupus ◽  
Serious Adverse Events

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs and tissues. Mesenchymal stem cells (MSCs) are considered a good source for autoimmune disease and hematological disease therapy. This review will summarize the efficacy, safety, and mechanisms of MSC therapy for SLE. MSC therapy can reduce anti-dsDNA, antinuclear antigen (ANA), proteinuria, and serum creatinine in SLE patients. In animal models of SLE, MSC therapy also indicates that it could reduce anti-dsDNA, ANA, proteinuria, and serum creatinine and ameliorate renal pathology. There are no serious adverse events, treatment-related mortality, or tumor-related events in SLE patients after stem cell treatment. MSCs can inhibit inflammatory factors, such as MCP-1 and HMGB-1, and inhibit inflammation-related signaling pathways, such as the NF-κB, JAK/STAT, and Akt/GSK3β signaling pathways, to alleviate the lesions in SLE.

Comparison of non-invasive assessment of arrhythmias, conduction disturbances and cardiac autonomic tone in systemic sclerosis and systemic lupus erythematosus

2018 ◽  
Vol 39 (2) ◽  
pp. 301-310 ◽  
Author(s):  
Piotr Bienias ◽  
Michał Ciurzyński ◽  
Bartłomiej Kisiel ◽  
Anna Chrzanowska ◽  
Katarzyna Ciesielska ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Systemic Sclerosis ◽  
Lupus Erythematosus ◽  
Autonomic Tone ◽  
Systemic Lupus ◽  
Conduction Disturbances ◽  
Non Invasive

scholarly journals Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus

Cells ◽  
2019 ◽  
Vol 8 (9) ◽  
pp. 963 ◽  
Author(s):  
I-Tsu Chyuan ◽  
Hong-Tai Tzeng ◽  
Ji-Yih Chen
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Autoimmune Diseases ◽  
Signaling Pathways ◽  
Lupus Erythematosus ◽  
Janus Kinase ◽  
Type I ◽  
Systemic Lupus ◽  
Type Iii ◽  
Signature Genes

Type I and type III interferons (IFNs) share several properties in common, including the induction of signaling pathways, the activation of gene transcripts, and immune responses, against viral infection. Recent advances in the understanding of the molecular basis of innate and adaptive immunity have led to the re-examination of the role of these IFNs in autoimmune diseases. To date, a variety of IFN-regulated genes, termed IFN signature genes, have been identified. The expressions of these genes significantly increase in systemic lupus erythematosus (SLE), highlighting the role of type I and type III IFNs in the pathogenesis of SLE. In this review, we first discussed the signaling pathways and the immunoregulatory roles of type I and type III IFNs. Next, we discussed the roles of these IFNs in the pathogenesis of autoimmune diseases, including SLE. In SLE, IFN-stimulated genes induced by IFN signaling contribute to a positive feedback loop of autoimmunity, resulting in perpetual autoimmune inflammation. Based on this, we discussed the use of several specific IFN blocking strategies using anti-IFN-α antibodies, anti-IFN-α receptor antibodies, and IFN-α-kinoid or downstream small molecules, which intervene in Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathways, in clinical trials for SLE patients. Hopefully, the development of novel regimens targeting IFN signaling pathways will shed light on promising future therapeutic applications for SLE patients.

Sign in / Sign up

Export Citation Format

Share Document